Ribociclib-induced Vitiligo in Advanced Stage Breast Cancer: Two Case Reports
Keywords:
Vitiligo, Cutaneous Adverse Event, Ribociclib, Cyclin-dependent Kinase 4/6 InhibitorsAbstract
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including ribociclib, have markedly improved therapeutic outcomes for patients with hormone receptor-positive advanced breast cancer. While generally well-tolerated, these agents can cause various adverse effects, some of which are infrequent and may be underrecognized. Vitiligo is a rare but potentially distressing cutaneous side effect of CDK4/6 inhibitors. We present two cases of vitiligo occurring in patients receiving ribociclib therapy for advanced breast cancer. The first case involves a 68-year-old woman who developed depigmented macules on her face and extremities after 22 months of treatment. Ribociclib was discontinued due to disease progression, but the depigmented lesions worsen. The second case features a 55-year-old woman who developed similar lesions six months after beginning ribociclib therapy.
References
Johnston S, Emde A, Barrios C, et al. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences. JNCI Cancer Spectr 2023;7:pkad045.
Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol 2020;20:669-79.
Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice. Ann Dermatol Venereol 2023;150:208-12.
Sollena P, Nikolaou V, Soupos N, et al. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat 2021;185:247-53.
Ma J, Chen K, Luan C. Cutaneous adverse events under new clinical therapies: drug-induced vitiligo-like depigmentation. Int J Dermatol Venereol 2024.
Kothari R, Darling HS, Bhatnagar A, Janney M, Mohan S, Kumar R. Ribociclib induced vitiligo-like lesions. Indian J Dermatol Venereol Leprol 2024;91:396-7.
Bang AS, Fay CJ, LeBoeuf NR, et al. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Res Treat 2024;204:643-7.
Anjaneyan G, Keechilat P, Duraisamy P, Eapen M. Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation. BMJ Case Rep 2022;15:e248782.
Pasqualoni M, Orlandi A, Palazzo A, et al. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Front Oncol. 2023;13:1067264.
Borroni RG, Bartolini M, Gaudio M, et al. Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication. Oncologist. 2024;29:484-92.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Thai Journal of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น
